Vonoprazan Fumarate is a potassium-competitive acid blocker that is the first of its kind. It received market approval in Japan in February 2015.

P-CABs, such as vonoprazan, are a novel and heterogeneous class of medicines that completely block the potassium binding site of gastric H+/K+ ATPase, potentially circumventing the limits of proton-pump inhibitors.

Vonoprazan fumarate is used to treat gastroduodenal ulcers (including some drug-induced peptic ulcers) and reflux esophagitis, and it can be used in conjunction with antibiotics to eradicate Helicobacter pylori.

Vonoprazan-amoxicillin co-packaged combinations and vonoprazan-amoxicillin and clarithromycin co-packaged combinations were approved for medicinal use in the United States in May 2022.

Post a Comment

Previous Post Next Post